| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Palmitic acid-d17 has no pharmacological target. Its biological relevance is as a substrate for fatty acid activation, carnitine shuttle transport, and mitochondrial β-oxidation. The deuterium label enables mass-spectrometric tracking of palmitate-derived carbons into acetyl-CoA, ketone bodies, and tricarboxylic-acid-cycle intermediates.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, palmitic acid-d17 is used as a tracer in β-oxidation assays with isolated mitochondria, cell homogenates, or cultured cells. It is complexed to BSA for cell culture and incubated for 1–4 hours at 37°C in a controlled atmosphere. Labeled acetyl-carnitine and β-hydroxybutyrate are quantified by LC-MS/MS or GC-MS. |
| ln Vivo |
In vivo, palmitic acid-d17 is administered orally in a meal or intravenously as a tracer. Oxidation is measured by the appearance of deuterium in body water or by quantification of labeled metabolites in plasma. The method eliminates the need for rigid environmental control and provides a cumulative record of fat oxidation.
|
| Enzyme Assay |
For in vitro β-oxidation, palmitic acid-d17 is conjugated to fatty-acid-free BSA and incubated with mitochondria or cell homogenates in the presence of cofactors (CoA, NAD⁺, FAD, carnitine). Labeled acyl-carnitines and acetyl-CoA are quantified by LC-MS/MS. For in vivo tracer studies, labeled palmitate is administered, and deuterium enrichment in body water is measured by isotope-ratio mass spectrometry.
|
| Cell Assay |
For cell-based tracer metabolomics, cells are incubated with palmitate-d17-BSA conjugate for 1–4 hours at 37°C. Metabolites are extracted with cold methanol/water and analyzed by LC-MS/MS to quantify labeled acetyl-CoA, citrate, and malate. This identifies pathways relying on fatty acid oxidation and quantifies the relative contribution of palmitate-derived carbons.
|
| Animal Protocol |
For in vivo studies, palmitic acid-d17 is administered orally or intravenously to rodents or humans. Plasma and tissue samples are collected at serial time points, and labeled palmitate and its metabolites are quantified by GC-MS or LC-MS/MS. Deuterium appearance in body water provides a cumulative measure of whole-body fat oxidation.
|
| References |
| Molecular Formula |
C16H32O2
|
|---|---|
| Molecular Weight |
273.528834342957
|
| Exact Mass |
273.347
|
| CAS # |
81462-28-4
|
| Related CAS # |
Palmitic acid;57-10-3
|
| PubChem CID |
90477412
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.552
|
| tPSA |
37.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
18
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)O
|
| InChi Key |
IPCSVZSSVZVIGE-OISRNESJSA-N
|
| InChi Code |
InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)/i1D3,2D2,3D2,4D2,5D2,6D2,7D2,8D2
|
| Chemical Name |
9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-heptadecadeuteriohexadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6559 mL | 18.2795 mL | 36.5591 mL | |
| 5 mM | 0.7312 mL | 3.6559 mL | 7.3118 mL | |
| 10 mM | 0.3656 mL | 1.8280 mL | 3.6559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.